JP2024531346A5 - - Google Patents

Info

Publication number
JP2024531346A5
JP2024531346A5 JP2024509419A JP2024509419A JP2024531346A5 JP 2024531346 A5 JP2024531346 A5 JP 2024531346A5 JP 2024509419 A JP2024509419 A JP 2024509419A JP 2024509419 A JP2024509419 A JP 2024509419A JP 2024531346 A5 JP2024531346 A5 JP 2024531346A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
substitution
residue
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024509419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/073145 external-priority patent/WO2023021169A1/en
Publication of JP2024531346A publication Critical patent/JP2024531346A/ja
Publication of JP2024531346A5 publication Critical patent/JP2024531346A5/ja
Pending legal-status Critical Current

Links

JP2024509419A 2021-08-20 2022-08-19 半減期が延長された抗体およびIgG融合タンパク質 Pending JP2024531346A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163235261P 2021-08-20 2021-08-20
US202163235259P 2021-08-20 2021-08-20
US63/235,259 2021-08-20
US63/235,261 2021-08-20
US202263341443P 2022-05-13 2022-05-13
US63/341,443 2022-05-13
PCT/EP2022/073145 WO2023021169A1 (en) 2021-08-20 2022-08-19 Antibodies and igg fusion proteins with an extended half-life

Publications (2)

Publication Number Publication Date
JP2024531346A JP2024531346A (ja) 2024-08-29
JP2024531346A5 true JP2024531346A5 (cg-RX-API-DMAC7.html) 2025-08-22

Family

ID=83280226

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024509419A Pending JP2024531346A (ja) 2021-08-20 2022-08-19 半減期が延長された抗体およびIgG融合タンパク質

Country Status (7)

Country Link
US (1) US20250197514A1 (cg-RX-API-DMAC7.html)
EP (1) EP4388004A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024531346A (cg-RX-API-DMAC7.html)
AU (1) AU2022329459A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227716A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024002150A (cg-RX-API-DMAC7.html)
WO (1) WO2023021169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3526246A1 (en) 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
BR112020015006A2 (pt) 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada
EP3866842A4 (en) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
KR20220066002A (ko) 2019-03-20 2022-05-23 킨드레드 바이오사이언시스, 인코포레이티드 의학적 용도의 ngf 길항제
FR3104217B1 (fr) 2019-12-10 2021-12-24 Innov Shoes Dispositif d’assemblage amovible entre deux pièces
WO2021123092A1 (en) * 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies for treating atopic dermatitis
JP7832123B2 (ja) 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法

Similar Documents

Publication Publication Date Title
AU2022218544B2 (en) Hetero-dimeric multi-specific antibody format
JP2024026255A5 (cg-RX-API-DMAC7.html)
JP7138046B2 (ja) 二特異性抗体基幹
JP2020195399A5 (cg-RX-API-DMAC7.html)
JP2024113039A (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2020517287A5 (cg-RX-API-DMAC7.html)
JP5480558B2 (ja) 改善された特異性を有する新規免疫グロブリン結合タンパク質
JP2023534636A5 (cg-RX-API-DMAC7.html)
JP2022512043A5 (cg-RX-API-DMAC7.html)
JP2020506898A5 (cg-RX-API-DMAC7.html)
JP2021511830A5 (cg-RX-API-DMAC7.html)
JP2024073531A5 (cg-RX-API-DMAC7.html)
JP2012515556A5 (cg-RX-API-DMAC7.html)
JP2023522029A5 (cg-RX-API-DMAC7.html)
JP2025146887A (ja) 多重特異性抗体混合物の生成およびその使用方法
JP2023553697A5 (cg-RX-API-DMAC7.html)
JP2017519503A5 (cg-RX-API-DMAC7.html)
JP2024547218A5 (cg-RX-API-DMAC7.html)
JP2021506310A5 (cg-RX-API-DMAC7.html)
JP2017518770A (ja) 新規ポリペプチド
JP2023542737A5 (cg-RX-API-DMAC7.html)
TW202204423A (zh) 用於產生和純化多價免疫球蛋白單可變域的方法
JP2024522092A5 (cg-RX-API-DMAC7.html)
JP2019172702A (ja) 目的とする含量で不純物を含むTNFR−Fc融合タンパク質の製造方法